WO2003030635A1 - A herbal hepatoprotective and weight gain promoter and a process thereof - Google Patents
A herbal hepatoprotective and weight gain promoter and a process thereof Download PDFInfo
- Publication number
- WO2003030635A1 WO2003030635A1 PCT/IN2001/000178 IN0100178W WO03030635A1 WO 2003030635 A1 WO2003030635 A1 WO 2003030635A1 IN 0100178 W IN0100178 W IN 0100178W WO 03030635 A1 WO03030635 A1 WO 03030635A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- plant
- powder
- herbal
- liver
- Prior art date
Links
- 235000019786 weight gain Nutrition 0.000 title claims abstract description 31
- 230000004584 weight gain Effects 0.000 title claims abstract description 30
- 230000002443 hepatoprotective effect Effects 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 5
- 230000008569 process Effects 0.000 title claims abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 101
- 241000196324 Embryophyta Species 0.000 claims abstract description 57
- 244000061457 Solanum nigrum Species 0.000 claims abstract description 15
- 235000002594 Solanum nigrum Nutrition 0.000 claims abstract description 15
- 244000118350 Andrographis paniculata Species 0.000 claims abstract description 13
- 244000173207 Phyllanthus amarus Species 0.000 claims abstract description 13
- 241000222666 Boerhavia diffusa Species 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims abstract 2
- 241001465754 Metazoa Species 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 31
- 230000001737 promoting effect Effects 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 5
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 claims description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 229960003168 bronopol Drugs 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 claims description 3
- 229940038472 dicalcium phosphate Drugs 0.000 claims description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 claims description 3
- 229960003476 methylparaben sodium Drugs 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 3
- 239000003755 preservative agent Substances 0.000 claims description 3
- 229960005359 propylparaben sodium Drugs 0.000 claims description 3
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 3
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 238000007796 conventional method Methods 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000271566 Aves Species 0.000 description 41
- 210000004185 liver Anatomy 0.000 description 28
- 230000017448 oviposition Effects 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 16
- 239000003814 drug Substances 0.000 description 15
- 235000013601 eggs Nutrition 0.000 description 14
- 229910052785 arsenic Inorganic materials 0.000 description 13
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 13
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 241000287828 Gallus gallus Species 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 11
- 244000144977 poultry Species 0.000 description 11
- 235000013594 poultry meat Nutrition 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000003925 fat Substances 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229930195730 Aflatoxin Natural products 0.000 description 7
- GWBPFRGXNGPPMF-UHFFFAOYSA-N N-[4-[(4-nitrophenyl)sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1 GWBPFRGXNGPPMF-UHFFFAOYSA-N 0.000 description 7
- 239000005409 aflatoxin Substances 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 230000003389 potentiating effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229950004215 sulfanitran Drugs 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 231100000234 hepatic damage Toxicity 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000008818 liver damage Effects 0.000 description 6
- 230000003908 liver function Effects 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 235000013372 meat Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical compound OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 description 5
- GFGSZUNNBQXGMK-UHFFFAOYSA-N 2-chloro-4-nitrobenzamide Chemical compound NC(=O)C1=CC=C([N+]([O-])=O)C=C1Cl GFGSZUNNBQXGMK-UHFFFAOYSA-N 0.000 description 4
- UUKWKUSGGZNXGA-UHFFFAOYSA-N 3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UUKWKUSGGZNXGA-UHFFFAOYSA-N 0.000 description 4
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 4
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229950009418 aklomide Drugs 0.000 description 4
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 description 4
- 230000000711 cancerogenic effect Effects 0.000 description 4
- 231100000315 carcinogenic Toxicity 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000006052 feed supplement Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000007952 growth promoter Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960003052 roxarsone Drugs 0.000 description 4
- 238000003307 slaughter Methods 0.000 description 4
- 239000004184 Avoparcin Substances 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241001164374 Calyx Species 0.000 description 3
- 206010019851 Hepatotoxicity Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000000507 anthelmentic effect Effects 0.000 description 3
- 230000001929 anti-hepatotoxic effect Effects 0.000 description 3
- 235000019377 avoparcin Nutrition 0.000 description 3
- 108010053278 avoparcin Proteins 0.000 description 3
- JWFVWARSGMYXRN-HTQQBIQNSA-N avoparcin Chemical compound O([C@H]1[C@H](C(N[C@H](C(=O)N[C@H]2C(=O)N[C@H]3C(=O)N[C@H](C(N[C@H](C4=CC(O)=CC(O)=C4C=4C(O)=CC=C3C=4)C(O)=O)=O)CC3=C(O[C@@H]4O[C@@H](C)[C@H](O)[C@H](N)C4)C=C(C(=C3)Cl)OC=3C=C2C=C(C=3O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@H](N)C2)OC2=CC=C1C=C2)C=1C=CC(O)=CC=1)=O)NC(=O)[C@@H](NC)C=1C=CC(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)=CC=1)[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@H]1O JWFVWARSGMYXRN-HTQQBIQNSA-N 0.000 description 3
- 229950001335 avoparcin Drugs 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000001784 detoxification Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000003912 environmental pollution Methods 0.000 description 3
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 3
- 231100000304 hepatotoxicity Toxicity 0.000 description 3
- 230000007686 hepatotoxicity Effects 0.000 description 3
- 229930013686 lignan Natural products 0.000 description 3
- 235000009408 lignans Nutrition 0.000 description 3
- 150000005692 lignans Chemical class 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 231100000219 mutagenic Toxicity 0.000 description 3
- 230000003505 mutagenic effect Effects 0.000 description 3
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000010457 zeolite Substances 0.000 description 3
- LBJCUHLNHSKZBW-XGHQBKJUSA-N (7r,8r,9s)-9-(3,4-dimethoxyphenyl)-4-methoxy-7,8-bis(methoxymethyl)-6,7,8,9-tetrahydrobenzo[g][1,3]benzodioxole Chemical compound C1([C@H]2C3=C4OCOC4=C(OC)C=C3C[C@H]([C@@H]2COC)COC)=CC=C(OC)C(OC)=C1 LBJCUHLNHSKZBW-XGHQBKJUSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 241000746375 Andrographis Species 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241001260012 Bursa Species 0.000 description 2
- ZDPIZLCVJAAHHR-UHFFFAOYSA-N Clopidol Chemical compound CC1=NC(C)=C(Cl)C(O)=C1Cl ZDPIZLCVJAAHHR-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- MMDWBZHWHFGVHF-UHFFFAOYSA-N Dinsed Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)NCCNS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 MMDWBZHWHFGVHF-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- LBJCUHLNHSKZBW-UHFFFAOYSA-N Hypophyllanthin Natural products COCC1C(COC)CC2=CC(OC)=C3OCOC3=C2C1C1=CC=C(OC)C(OC)=C1 LBJCUHLNHSKZBW-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000019780 Liver Tonic Nutrition 0.000 description 2
- NNOPDLNHPOLRRE-UHFFFAOYSA-N Nequinate Chemical compound CCCCC1=CC(C(C(C(=O)OC)=CN2)=O)=C2C=C1OCC1=CC=CC=C1 NNOPDLNHPOLRRE-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- UKHWDRMMMYWSFL-UHFFFAOYSA-N Nicarbazin Chemical compound CC=1C=C(C)NC(=O)N=1.C1=CC([N+](=O)[O-])=CC=C1NC(=O)NC1=CC=C([N+]([O-])=O)C=C1 UKHWDRMMMYWSFL-UHFFFAOYSA-N 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- KFLQGJQSLUYUBF-WOJBJXKFSA-N Phyllanthin Chemical compound C([C@H](COC)[C@@H](COC)CC=1C=C(OC)C(OC)=CC=1)C1=CC=C(OC)C(OC)=C1 KFLQGJQSLUYUBF-WOJBJXKFSA-N 0.000 description 2
- KFLQGJQSLUYUBF-PMACEKPBSA-N Phyllanthin Natural products C([C@@H](COC)[C@H](COC)CC=1C=C(OC)C(OC)=CC=1)C1=CC=C(OC)C(OC)=C1 KFLQGJQSLUYUBF-PMACEKPBSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229950007851 dinsed Drugs 0.000 description 2
- -1 diterpenoid lactone Chemical class 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000000876 liver tonic Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960001907 nitrofurazone Drugs 0.000 description 2
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 2
- 229960000625 oxytetracycline Drugs 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- MOOFYEJFXBSZGE-KFSYKRRRSA-N robenidine Chemical compound C1=CC(Cl)=CC=C1\C=N\NC(=N)N\N=C/C1=CC=C(Cl)C=C1 MOOFYEJFXBSZGE-KFSYKRRRSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- VUEPOIYXKZTLMD-ANZZXSATSA-N (3e,4s)-3-[2-[(1r,4as,5r,6r,8as)-6-hydroxy-5,8a-dimethyl-2-methylidene-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one Chemical compound C([C@@]1(C)[C@H]2CCC(=C)[C@@H](C\C=C/3C(OC[C@H]\3O)=O)[C@]2(C)CC[C@H]1O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VUEPOIYXKZTLMD-ANZZXSATSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- NBOODGNJLRRJNA-IAGPQMRQSA-N 2-[(4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl Chemical compound OP(O)(O)=O.O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 NBOODGNJLRRJNA-IAGPQMRQSA-N 0.000 description 1
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 description 1
- YGCYRQKJYWQXHG-RDNQFMDVSA-N 4-[2-[(1r,4as,5r,8as)-5,8a-dimethyl-2-methylidene-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@@]1(C)[C@H]2CCC(=C)[C@@H](CCC=3C(OCC=3)=O)[C@]2(C)CCC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YGCYRQKJYWQXHG-RDNQFMDVSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- QKLPUVXBJHRFQZ-UHFFFAOYSA-N 4-amino-n-(6-chloropyrazin-2-yl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=CC(Cl)=N1 QKLPUVXBJHRFQZ-UHFFFAOYSA-N 0.000 description 1
- KEEYRKYKLYARHO-UHFFFAOYSA-N 5-[(4,5-dimethoxy-2-methylphenyl)methyl]pyrimidine-2,4-diamine Chemical compound C1=C(OC)C(OC)=CC(C)=C1CC1=CN=C(N)N=C1N KEEYRKYKLYARHO-UHFFFAOYSA-N 0.000 description 1
- COCLLEMEIJQBAG-UHFFFAOYSA-N 8-methylnonyl 2-methylprop-2-enoate Chemical compound CC(C)CCCCCCCOC(=O)C(C)=C COCLLEMEIJQBAG-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930188120 Carbomycin Natural products 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241001573881 Corolla Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000006479 Cyme Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 240000000630 Hedysarum occidentale Species 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930191564 Monensin Natural products 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 241000219469 Nyctaginaceae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000004104 Oleandomycin Substances 0.000 description 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241001130943 Phyllanthus <Aves> Species 0.000 description 1
- 241001152628 Phyllanthus debilis Species 0.000 description 1
- 208000009989 Posterior Leukoencephalopathy Syndrome Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 244000052585 Rosa centifolia Species 0.000 description 1
- 235000016588 Rosa centifolia Nutrition 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- MBWUSSKCCUMJHO-ZGXDEBHDSA-N Solamargine Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O MBWUSSKCCUMJHO-ZGXDEBHDSA-N 0.000 description 1
- MBWUSSKCCUMJHO-DVDUUUGDSA-N Solamargine Natural products O([C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@@H](C)[C@@]6(O[C@H]5C4)NC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](C)O1 MBWUSSKCCUMJHO-DVDUUUGDSA-N 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- KNLOWJPFLKGYGQ-UHFFFAOYSA-N Solasodine 3-O-??-L-rhamnopyranosyl (1‘Â∆2)-O-[??-D-glucopyranosyl (1‘Â∆4)]-??-D-glucopyranoside Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(CO)C(O)C(O)C1O KNLOWJPFLKGYGQ-UHFFFAOYSA-N 0.000 description 1
- QCTMYNGDIBTNSK-UHFFFAOYSA-N Solasonin Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O QCTMYNGDIBTNSK-UHFFFAOYSA-N 0.000 description 1
- QCTMYNGDIBTNSK-QCNFCIKQSA-N Solasonine Natural products O([C@@H]1[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O2)[C@@H](O[C@@H]2CC=3[C@@](C)([C@@H]4[C@H]([C@H]5[C@@](C)([C@H]6[C@@H](C)[C@@]7(O[C@H]6C5)NC[C@H](C)CC7)CC4)CC=3)CC2)O[C@@H](CO)[C@@H]1O)[C@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 QCTMYNGDIBTNSK-QCNFCIKQSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- RCTKRNCKOYYRIO-UHFFFAOYSA-N alpha-Solamarine Natural products O1C2(NCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C1O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O RCTKRNCKOYYRIO-UHFFFAOYSA-N 0.000 description 1
- LCTXBFGHZLGBNU-UHFFFAOYSA-M amprolium Chemical compound [Cl-].NC1=NC(CCC)=NC=C1C[N+]1=CC=CC=C1C LCTXBFGHZLGBNU-UHFFFAOYSA-M 0.000 description 1
- 229960003683 amprolium Drugs 0.000 description 1
- 229930185870 andrographidine Natural products 0.000 description 1
- FAONOYVYMFUUOU-UHFFFAOYSA-N andrographiside Natural products CC1(COC2OC(CO)C(O)C(O)C2O)C(O)CCC3(C)C(CC=C4/C(O)OCC4=O)C(=C)CCC13 FAONOYVYMFUUOU-UHFFFAOYSA-N 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- XKNKHVGWJDPIRJ-UHFFFAOYSA-N arsanilic acid Chemical compound NC1=CC=C([As](O)(O)=O)C=C1 XKNKHVGWJDPIRJ-UHFFFAOYSA-N 0.000 description 1
- 229950002705 arsanilic acid Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229930187356 boeravinone Natural products 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229950003639 buquinolate Drugs 0.000 description 1
- 210000001669 bursa of fabricius Anatomy 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 229950005779 carbomycin Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 239000000731 choleretic agent Substances 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960000731 clopidol Drugs 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical compound N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 229960001878 decoquinate Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- MEEPUSVTMHGIPC-UHFFFAOYSA-N deoxyandrographiside Natural products OC1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O MEEPUSVTMHGIPC-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 125000000567 diterpene group Chemical group 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- LVVXOXRUTDAKFE-UHFFFAOYSA-N ethyl 6,7-bis(2-methylpropoxy)-4-oxo-1h-quinoline-3-carboxylate Chemical compound CC(C)COC1=C(OCC(C)C)C=C2C(=O)C(C(=O)OCC)=CNC2=C1 LVVXOXRUTDAKFE-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000004121 glycogenesis Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960003284 iron Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 229960005307 lasalocid sodium Drugs 0.000 description 1
- RDHDUYAKDYQPEW-HWLWSTNVSA-M lasalocid sodium Chemical compound [Na+].C([C@@H]1[C@@]2(CC)O[C@@H]([C@H](C2)C)[C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)CCC=2C(=C(O)C(C)=CC=2)C([O-])=O)C[C@](O)(CC)[C@H](C)O1 RDHDUYAKDYQPEW-HWLWSTNVSA-M 0.000 description 1
- 208000027906 leg weakness Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- FPGCYQVKNKEGRQ-SXLQGMKLSA-N methyl (1r,15s,17s,18r,19s,20s)-6,17,18-trimethoxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate Chemical compound COC1=CC=C2C(CCN3C[C@H]4C[C@@H]([C@@H]([C@H]([C@H]4C[C@@H]33)C(=O)OC)OC)OC)=C3NC2=C1 FPGCYQVKNKEGRQ-SXLQGMKLSA-N 0.000 description 1
- 229950003942 metoserpate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229960005358 monensin Drugs 0.000 description 1
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- BBGWVUQBIGGVLS-UHFFFAOYSA-N neoandrographolide Natural products CC1(COC2OC(CO)C(O)C(O)C2O)C(O)CCC3(C)C(CCC4=C(O)COC4=O)C(=C)CCC13 BBGWVUQBIGGVLS-UHFFFAOYSA-N 0.000 description 1
- YGCYRQKJYWQXHG-UHFFFAOYSA-N neoandrographoside Natural products C1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O YGCYRQKJYWQXHG-UHFFFAOYSA-N 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229950002796 nequinate Drugs 0.000 description 1
- 229940073485 nicarbazin Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- FUUFQLXAIUOWML-UHFFFAOYSA-N nitarsone Chemical compound O[As](O)(=O)C1=CC=C([N+]([O-])=O)C=C1 FUUFQLXAIUOWML-UHFFFAOYSA-N 0.000 description 1
- 229960003985 nitarsone Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 235000019367 oleandomycin Nutrition 0.000 description 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
- 229960002351 oleandomycin Drugs 0.000 description 1
- 229960003068 ormetoprim Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WXTCDCIGKZBCDB-QUXGMGRISA-A pentadecasodium [2-[(2S,5R,8S,11S,14S,17S,22S)-5-benzyl-17-[(1R)-1-hydroxyethyl]-22-[[(2S)-2-[[(2S,3S)-3-hydroxy-2-[[(2S)-2-(6-methylheptanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-8-(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate [2-[(2S,5R,8S,11S,14S,17S,22S)-5-benzyl-17-[(1R)-1-hydroxyethyl]-22-[[(2S)-2-[[(2S,3S)-3-hydroxy-2-[[(2S)-2-[[(6S)-6-methyloctanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-8-(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate [2-[(2S,5R,8S,11S,14S,17S,22S)-5-benzyl-17-[(1R)-1-hydroxyethyl]-22-[[(2S)-2-[[(2S,3S)-3-hydroxy-2-[[(2S)-2-(octanoylamino)-4-(sulfonatomethylamino)butanoyl]amino]butanoyl]amino]-4-(sulfonatomethylamino)butanoyl]amino]-8-(2-methylpropyl)-3,6,9,12,15,18,23-heptaoxo-11,14-bis[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-2-yl]ethylamino]methanesulfonate Chemical compound CCCCCCCC(=O)N[C@@H](CCNCS(=O)(=O)[O-])C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCNCS(=O)(=O)[O-])C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCNCS(=O)(=O)[O-])CC2=CC=CC=C2)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCNCS(=O)(=O)[O-])C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCNCS(=O)(=O)[O-])C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CCNCS(=O)(=O)[O-])CC2=CC=CC=C2)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])[C@@H](C)O.C[C@H]([C@H]1C(=O)NCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])CC(C)C)CC2=CC=CC=C2)CCNCS(=O)(=O)[O-])NC(=O)[C@H](CCNCS(=O)(=O)[O-])NC(=O)[C@H]([C@H](C)O)NC(=O)[C@H](CCNCS(=O)(=O)[O-])NC(=O)CCCCC(C)C)O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] WXTCDCIGKZBCDB-QUXGMGRISA-A 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- XFNRKNPALRWYCF-UHFFFAOYSA-N punarnavoside Natural products OCC1OC(Oc2cc(O)c(OC(=O)CCc3ccc(O)cc3)cc2Cc4ccccc4)C(O)C(O)C1O XFNRKNPALRWYCF-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960004591 robenidine Drugs 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 1
- 235000017700 silymarin Nutrition 0.000 description 1
- 229960004245 silymarin Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- OUFRIWNNMFWZTM-UHFFFAOYSA-M sodium arsanilate Chemical compound [Na+].NC1=CC=C([As](O)([O-])=O)C=C1 OUFRIWNNMFWZTM-UHFFFAOYSA-M 0.000 description 1
- XOIQMTLWECTKJL-HXPDMXKUSA-M sodium;(3r,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-ethyl-5-[(2r,3s,5r)-5-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]oxolan-2-yl]-7-hydroxy-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoate Chemical compound [Na+].C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)C(C)C([O-])=O)O2 XOIQMTLWECTKJL-HXPDMXKUSA-M 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 229960003097 sulfaquinoxaline Drugs 0.000 description 1
- 229950003233 sulfomyxin Drugs 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940031989 tylosin phosphate Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 description 1
- QCTMYNGDIBTNSK-XEAAVONHSA-N α-Solamarine Chemical compound O([C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(NC[C@H](C)CC1)O5)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QCTMYNGDIBTNSK-XEAAVONHSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
Definitions
- the present invention relates to a novel herbal composition useful for hepatoprotection and promoting weight gain in domestic animals.
- One embodiment of the present invention resides in providing a herbal composition which is synergistically effective in promoting weight gain in domestic animals such as poultry, cattle etc through optimization of liver function.
- the composition of the present invention is also a very potent and effective liver tonic.
- the composition guards against toxins and toxic effects of feed contaminants and several chemical drugs. It helps to regenerate damaged liver tissues caused by infections, toxins and exhibits hepatogenic property through optimization of liver function.
- the composition is unique because of its multifunctional properties as well as its activity through optimization of liver functions.
- compositions having such multifunctional properties and activity through optimization of liver functions to promote weight gain in domestic animals are hitherto not known either in modern medicine or other hitherto marketed herbal products.
- the composition is equally useful in case of Aflatoxicosis and also improper fat metabolism in domestic animals.
- the composition is a choleretic and thus it normalises fat metabolism and in turn causes improvement in poor feed conversions.
- Livestock suffer from drop in optimum functioning of liver, caused by toxins, chemical drugs, certain feed contaminants, parasitism, infections etc.
- the present invention serves as a highly efficient liver tonic, rectifies deranged liver and optimizes all liver functions. Similarly poultry birds so susceptible to above factors and often suffer from liver problems.
- Liver is considered to be one of the most important organs of human beings and animals. It is responsible for maintaining the body ' s metabolic homeostasis.
- the liver serves many functions, including regulation of blood volume and manufacture of certain blood clotting factors, the storage of several substances, including glycogen, copper, iron and Vitamin B ⁇ 2 ; the metabolism of proteins, carbohydrates, and fats; production of heat; detoxification (removing the poisonous effect) of certain foreign substances in the blood; destruction of old red blood cells; and formation of bile.
- liver Specialized functions of the liver that can be emphasized include processing of dietary amino acids, carbohydrates, lipids and vitamins, phagoc>1osis of particulate material in the splanchnic circulation, synthesis of serum proteins, bio-transformation of circulating metabolites and detoxification and excretion into bile of endogenous waste products.
- the variety of functions performed by the liver makes it vulnerable to a wide variety of metabolic, toxic, microbial. circulatory and neoplastic related diseases.
- Primary diseases of liver include jaundice, hepatitis and cirrhosis of the liver. Secondary diseases of the liver are generally the damages caused in cases of l alcoholism, cardiac decomposition, extrahepatic infections and the like. Consequences of a deranged liver are generally life threatening and often fatal.
- Digestion is a very important and vital function carried out by the body both in animals and humans which serves as an energy generator to run the body mechanisms. Improper digestion apart from causing discomfiture also results in incomplete absorption and assimilation of nutrients and hence poor feed conversion. The poor feed conversion in turn affects general health of the domestic animals such poultry, cattle, birds etc as in the case of humans. Consequently, it results in reduced productivity, livability and hinders uniform sexual maturity. To counteract these effects and to positively promote growth, antibiotics have been in use for many years. Table- 1 lists the antibacterial growth promoters and toxin-binders available in the market.
- Zinc bacitracin 100-200 gms/tonne 2.
- Oxytetracycline 100-500gms/tonne Vergimamycin ⁇ 500 gms/tonne
- Antibiotics improve feed or water consumption or both. General health of the bird and feed conversion improves. It is reported that ceca of antibiotic fed chicken are larger and filled with greater quantity of moist excreta, compared to the ceca of chickens fed the same diet without an antibiotic.
- GIT Gastro Intestinal Tract
- a classic example is that of Avoparcin.
- Avoparcin was a well-known glycopetode antibiotic. which was used in many countries as a growth enhancer in various species of livestock including pigs and poultry. In 1995, this product was banned in Denmark and in Germany in 1996. It was banned for use in European Union in 1997. This was because of concerns that the use of Avoparcin was leading to the development of resistance against an important human medicine, Vancomycin and that the resistance could transfer from bacteria in the food chain to man. This could be important as Vancomycin is a so called 'antibiotic of last resort' in human medicine.
- Aklomide,roxarsone 5 Do not use in egg-laying birds; Aklomide: liver, use as only source of organic (Aklomix-3) muscle,4.5;skin,fat,3.Arseni arsenic c:muscle,eggs,0.5; other by- roducts,2
- Amprolium 0 For control only several Ei-meria Liver,kidney, 1 ; sp. muscle,0.5;whole eggs,4;egg yoiks,8 Arsenic, same as above
- Arsanilic acid or 5 Use as only source of organic Arsenic, same as above sodium arsanilate arsenic
- Buquinolate 5 Use as only source of organic Liver, arsenic kidney,skin,0.4;muscle,0.1 ; eggs,0.2(calculated as arsenic)
- Carbomycin 2 Do not use in egg-laying birds; 0
- Chlortetracycline 1 Do not use in egg-laying birds Kidney,4; when fed at 500g/900 kg feed muscle,liver,fat.skin, 1 ;eggs. 0
- Clopidol(Coyden) Do not use in chickens over 16 Liver and weeks old when feeding 0.025%, kidney, 15;muscle,5 or reduce dosage to 0.0125% 5 days before slaughter
- Estradiol 42 Injected subcutaneously at base ofO monopalmitate skull at not less than 5 weeks of
- Furazolidone (Furox 5 Do not use in egg-laying birds or None published NF-180) in replacements over 14 weeks old Gentamicin sulfate 35 For use in day-old chickens only None published injection
- Hygromycin B 0 8-12 g/900 kg feed 0
- Metoserpate Do not use in egg-laying birds 0.02 hydrochloride
- Nequinate(Statyl) Use as only source of organic Edible tissues,0.1 arsenic; do not use in chickens over 16 weeks old
- Nitromide,sulfanitran 5 Do not use in egg-laying birds Nitromide,none
- Nitromide.sulfanitran 5 Do not use ih egg-laying birds, Nitromide,0.03;sulfanitran.0 (Unistat-3) use as only source of organic ;arsenic, same as above arsenic ⁇ ____
- Oleandomycin Do not use in egg-laying birds Edible tissues,0.15 Ormetoprim 5 Do not use in birds over 16 week Edible tissues,0.1 old
- the present invention has been developed to meet the above said requirements Therefore the main objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals Another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which is very potent, non toxic and safe.
- Still another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which is not mutagenic or carcinogenic
- Yet another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which does not give rise to environmental pollution and is readily biodegradable.
- Another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which is non-toxic to the animal and its human handlers.
- Ayurveda Indian system of medicine recommends several medicinal plants useful as herbal feed supplements which are also effective in curing ailments of the liver.
- Ayurvedic literature like "Vaidya Chintamani, Bhava Prakash Niganthu, Yoga Ratnakara and Charaka Samhita” have references to the herbs capable of being used in the treatment of liver disorders.
- the present invention has been developed based on our finding that a synergistic hepatoprotective and weight gain promoting composition can be formulated to meet the above mentioned objectives employing plants judiciously selected from the families of Acanthaceae, Euphorbiaceae, Solanaceae and Nyctaginaceae. From the above said families of the plants used in Ayurveda for hepatoprotective and weight gain promoting in domestic animals we have selected according to the present invention the following plants.
- Medicinal uses: The plant is bitter, acrid, cooling, vulnerary, antipyretic, antiperiodic, anti- mflammatory, expectorant, depurative, sudoforic, anthelmintic, digestive and stomachic. It is useful in rryperdypsia, burning sensation, wounds, ulcers, chronic fever, malarial and intermittent fevers. irLflairirnations, cough, bronchitis, skin diseases, leprosy, pruritis, intestinal worms, flatulence colic.
- Andrographis paniculata The main constituents of Andrographis paniculata are diterepene lactones, viz.. andrographolide, neoandrographolide, andrographiside and flavones viz., oroxylin, wogonin, andrographidines A, B, C, D, E, F (Indian Herbal Pharmacopoeia, Vol. I, p.18-29. Joint Publication of IDMA (Mumbai) and RRL (Jammu-Tawi; Matsuda T, et al "Cell differentiation - Inducing Diterpenes from Andrographis pa iculata Nees", Chem. Pharm. Bull, 1994, 42(6),
- Hepatoprotective effect of andrographolide (the major active diterpenoid lactone of the plant Andrographis paniculata) was studied in many experimental models. In a study a dose of 300 mg/kg of the extract was selected to study hepatoprotective action against CC14-induced liver damage, was found to be effective in preventing liver damage, which was evident by morphological, biochemical and functional parameters (Rana, A.C; Avadhoot, Y;
- Andrographolide was found to be more potent than silymarin, a known hepatoprotective drug (Visen, P.K.S; Shukla, B; Patnaik,
- Botanical description An erect annual herb,, -stem glabrous or pubscent, much divaricately branched. Leaves numerous, ovate, lanceolate, subacute or accuminate, glabarous, thin entire.
- Medicinal uses The plant used as an antispasmodic and in the treatment of cirrhosis of the liver.
- the plant contains protein, fat, minerals, carbohydrates, riboflavin, nicotinic acid. vitamin-c, carotene, glucose, fructose, steroidal alkaloids viz. solamargine, solasonine, solanigrine. etc. (Wealth of Asia ,NISCOM. CSIR, New Delhi.1996)
- the hepatoprotective activity of Solanum nigrum crude plant extracts may be due to their ability to suppress the oxidative degradation of DNA in the tissue debris.
- (Sultana S., et a! "Crude extracts of hepatoprotective plants, Solanum nigrum and Cichorium intybus inhibit free radical-mediated DNA damage. " J. ofEthnopharmacology, 1995, 45, 189-192).
- BOERHAA VIA DIFFUSA Part used Whole plant Botanical description: A perennial diffuse herb with stout root stock and many procurement branches; leaves simple, opposite, short petioled in unequal pairs, ovate-oblong, acute or obtuse, subcordate at base, glabrous above and whitish beneath ; flowers pale rose colored, small, short stalked, in irregular clusters of terminal panicles at the ends of branches; fruits highly viscid, easily detachable, one-seeded, indehiscent with a thin pe ⁇ csrp(Indian Medicinal Plants, A compendium of 500 species, Orient Longman, 1993 ; Vol. 1 : 253-255)
- Medicinal uses The plant is bitter, astringent, cooling, anthelmintic, diuretic, emetic, expectorant. It is used in the treatment of jaundice (Wealth of Asia ,NISCOM, CSIR, New Delhi, 1996 lndian Medicinal Plants , A compendium of 500 species. Orient Longman, 1993; Vol. 1: 253-255)
- Pbytochemistry The major constituent namely Punarnavoside is found in 0.03-0.05%.Other minor consdtuents include rotenoids viz., boeravinones A,B,C,D, & E ; lignans liridodendrin etc.
- Botanical description A small erect herb, stem terete, younger parts rough; leaf elliptic oblong to obvate; Flowers axillary, proximal 2-3 axils with unisexual 1-3 male flowers and all succeeding axils with bisexual cymules. Male flowers-pedicel long, calyx 5, sub equal, oblong, elliptic, apex acute, hyaline with unbranched mid rib; disc segments 5, rounded, stamens 3. filaments connate.
- Medicinal uses The plant is bitter, astringent, cooling, diuretic, stomachic, febrifuge and antiseptic. It is useful in dropsy, jaundice, diarrhoea, dysentery, intermittent fevers, diseases of urino-genital system, scabies ulcers and wounds (Wealth of Asia, NISCOM, CSIR, New Delhi. 1996: Indian Medicinal Plants. A compendium of 500 species, Orient Longman. 1995; Vol. 4: 252- 255; Bhava prakash nigunia. Motilal banarsidas publications, 1998, 273) Phytochemistry: The major lignans Phyllanthin and Hypophyllanthin has been reported to exhibit antihepatotoxic activity.
- the alcoholic extracts were effective against HBV antigens, the butanol extract being the most potent.
- the active fractions inhibited the interaction between HBsAg/HbeAg and corresponding antibodies suggesting anti- HBs, anti-Hbe-like activity and also an effect on HBV-DNA.
- the crude powders of the above mentioned plants were administered individually to domestic animals ( Poultry birds) to determine the hepatoprotective and weight gain promoting activities in the following manner
- Plant 1 relates to Andrographis paniculata;
- Plant 2 relates to Solanum nigrum;
- Plant 3 relates to Phyllanthus amarus and
- Plant 4 relates to - Boerhaavia diffusa
- the present invention provides, a herbal composition useful for hepatoprotection and promoting weight gain in domestic animals comprising
- any part of the above said plants may be used individually or all the parts together as per the requirements .
- the composition may be formed into any oral dosage forms like, tablets, bolus, capsules, syrups and liquids etc.
- pharmaceutical excipients which are usually employed to prepare such oral dosage form may be employed .
- recipients like starch, pre- gelatinized starch, dicalcium phosphate or a mixture thereof may be used.
- a herbal composition may also contain preservatives which may be selected from propyl paraben sodium, methyl paraben sodium or bronopol or a mixture thereof and the like .
- any part of the above said plants individually or all the parts together may be used as per the requirements
- the parts of the plants or the whole plants are cleaned to avoid foreign materials , cut and chopped to make it easy to make the powders ..
- the composition may be formed into any oral dosage forms like, tablets, bolus, capsules, syrups and liquids etc by conventional means .
- pharmaceutical excipients which are usually employed to prepare such oral dosage form may be employed .
- recipients like starch, pre-gelatinized starch, dicalcium phosphate or a mixture thereof may be used.
- a herbal composition may also contain preservatives which may be selected from propyl paraben sodium, methyl paraben sodium or bronopol or a mixture thereof and the like .
- composition A An amount of 150gms (30%w/w) of Andrographis paniculata (whole plant) and lOOg s (20%/w) of Phyllanthus amarus (whole plant) were cleaned and chopped in a chopping machine to obtain a mesh size of 8 to 10 mesh and mixed together .
- the above said two mixtures were mixed together and the resulting composition was pulverised in a pulveriser to a sieve size of 70 to 100
- the above composition for convenience is henceforth referred to as Composition A
- Example 2 An amount of 125gms (25%w/w) of Andrographis paniculata (whole plant) and 150gms (30%/w) of Phyllanthus amarus (whole plant) were cleaned and chopped in a chopping machine to obtain a mesh size of 8 to 10 mesh and mixed together .
- 100 gms (20%w/w) of Solanum nigrum whole plant after cleaning and chopping was powdered in a hammer mill to a sieve size of 8 to 10 mesh was mixed with 125gms (25%w/w) of the powder having the mesh size of 8 to 10 of the plant Boerhaavia diffusa, (whole plant).
- the above said two mixtures were mixed together and the resulting composition was pulverised in a pulveriser to a sieve size of 70 to 100 5
- Composition B The above composition for convenience is henceforth referred to as Composition B
- Composition B (Example 2) treated group showed significant improvement over the aflatoxin fed birds in terms of body weight gain, feed consumption, FCR, etc.
- Test 1 shows- Example 1 (Composition A)
- Test 2 shows- Example 2 (Composition B)
- Composition B Example 2 was more potent it was selected for further studies.
- Composition B (Example 2) was tested for its efficacy at different dosages for its hepatoprotective and weight gain promoter activity in two different dosages to chicks (Vencobb hybrid line)
- Control group received the feed (Lipton's Gold Mohur feed from Malawistan Lever Limited) and treated groups received the same feed mixed with the required doses of the test material.
- the birds were fed for a period of 42 days. Feed consumption ratio, body weight, livability were recorded as the parameter.
- composition B Example 2 at 250g/ton dosage afforded maximum hepatoprotection and weight gain which was comparable with a dosage of 500g/tonne of feed. The results are given in Table 5
- Test 2 shows the Example 2 ( Composition B ) - 250 g/ton ;
- Test 2- shows the Example 2 ( Composition B ) 500g/ton
- composition of the present invention is not a mere admixture of the ingredients employed but is a result of a unexpected synergistic combination of the ingredients employed Study of acute toxicity of the Example 2(Composition B)
- composition B was tested for its efficacy as hepatoprotective in its crude drug form and as a liquid
- the liquid form of the Composition B was prepared by mixing the powder with water
- composition B (as powder) (as liquid)
- Composition B Field trials of Composition B in powder form were conducted at various agroclimatic condition, feeds and strains of birds in India on layers and broilers have shown an improvement in body weight, livability and production number. Composition B has also shown to reduce the egg shell breakage and reduce mortality in layers as can be seen from the Table 6 .
- composition B is very consistent and it is independent irrespective of strain of broiler, feed (branded/unbranded) and agro climatic conditions.
- the composition of the present invention also improves feed metabolism and digestion and thus helps in better growth, weight gain and general health. It acts in the following ways:
- the present invention has other advantages such as
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Fodder In General (AREA)
Abstract
The present invention relating to herbal hepatoprotective and weight gain promoter which comprises the synergistic mixture of whole plant of Andrographis paniculata, Solanum nigrum, Phyllanthus amarus and Boerhaavia diffusa. The present invention also relates to a process of preparation of such composition. The composition is particularly useful as hepatoprotective and weight gain promoter.
Description
"AHERBAL HEPATOPROTECTIVE AND WEIGHT GAIN
PROMOTERAND A PROCESS THEREOF"
The present invention relates to a novel herbal composition useful for hepatoprotection and promoting weight gain in domestic animals. One embodiment of the present invention resides in providing a herbal composition which is synergistically effective in promoting weight gain in domestic animals such as poultry, cattle etc through optimization of liver function. The composition of the present invention is also a very potent and effective liver tonic. The composition guards against toxins and toxic effects of feed contaminants and several chemical drugs. It helps to regenerate damaged liver tissues caused by infections, toxins and exhibits hepatogenic property through optimization of liver function. The composition is unique because of its multifunctional properties as well as its activity through optimization of liver functions. An herbal composition having such multifunctional properties and activity through optimization of liver functions to promote weight gain in domestic animals is hitherto not known either in modern medicine or other hitherto marketed herbal products. The composition is equally useful in case of Aflatoxicosis and also improper fat metabolism in domestic animals. The composition is a choleretic and thus it normalises fat metabolism and in turn causes improvement in poor feed conversions.
Livestock suffer from drop in optimum functioning of liver, caused by toxins, chemical drugs, certain feed contaminants, parasitism, infections etc. The present invention serves as a highly efficient liver tonic, rectifies deranged liver and optimizes all liver functions. Similarly poultry birds so susceptible to above factors and often suffer from liver problems.
Liver is considered to be one of the most important organs of human beings and animals. It is responsible for maintaining the body's metabolic homeostasis. The liver serves many functions, including regulation of blood volume and manufacture of certain blood clotting factors, the storage of several substances, including glycogen, copper, iron and Vitamin Bι2; the metabolism of proteins, carbohydrates, and fats; production of heat; detoxification (removing the poisonous effect) of certain foreign substances in the blood; destruction of old red blood cells; and formation of bile. Specialized functions of the liver that can be emphasized include processing of dietary amino acids, carbohydrates, lipids and vitamins, phagoc>1osis of particulate material in the splanchnic circulation, synthesis of serum proteins, bio-transformation of circulating metabolites and detoxification and excretion into bile of endogenous waste products. The variety of functions performed by the liver makes it vulnerable to a wide variety of metabolic, toxic, microbial. circulatory and neoplastic related diseases. Primary diseases of liver include jaundice, hepatitis and cirrhosis of the liver. Secondary diseases of the liver are generally the damages caused in cases of l
alcoholism, cardiac decomposition, extrahepatic infections and the like. Consequences of a deranged liver are generally life threatening and often fatal.
Digestion is a very important and vital function carried out by the body both in animals and humans which serves as an energy generator to run the body mechanisms. Improper digestion apart from causing discomfiture also results in incomplete absorption and assimilation of nutrients and hence poor feed conversion. The poor feed conversion in turn affects general health of the domestic animals such poultry, cattle, birds etc as in the case of humans. Consequently, it results in reduced productivity, livability and hinders uniform sexual maturity. To counteract these effects and to positively promote growth, antibiotics have been in use for many years. Table- 1 lists the antibacterial growth promoters and toxin-binders available in the market.
TABLE-1
ANTIBACTERIAL GROWTH PROMOTERS
_>duct Active ingredients Mixing Rate
1. Zinc bacitracin 100-200 gms/tonne 2. Oxytetracycline 100-500gms/tonne Vergimamycin^ 500 gms/tonne
4. FlavophosjΛolijrøl 100 gms/tonne TOXIN B INDERS
1. Organic acids, Gentian voi let and zeolites 2.5kgs-10kgs/tonne depending on moisture
2. Phytosilicates, Zeolites 500gms-2.5 kg tonne of feed
3. Zeolites, organic acids and probiotics 1.5 kgs/tonne of feed for moisture level upto 15%
However, treatment using antibiotics has its merits and demerits. Its merits are: l .They may inhibit the growth of microorganisms that produce excessive amounts of Ammonia and other toxic nitrogenous waste products in the intestine. The intestinal bacteria are altered in such a way that less urease is produced and thus lesser Ammonia is generated. Ammonia is a highly toxic gas (permissible level only 25 ppm) and suppresses the growth of birds.
2.They may improve the availability or absorption of certain nutrients like Calcium, Phosphorus. Magnesium, protein, amino acids and vitamins.
3. They eliminate pathogens causing sub-clinical infection. In many instances, they may actually cure pathological diseases (mainly confined to the intestinal tract) and control low disease levels which may be encountered even in good, healthy poultry.
4.They destroy the microbial flora causing inflammation (therefore swelling and thickening of the intestinal wall), and thus help to maintain thinner intestinal wall and thereby effect better absorption of nutrients.
5.Antibiotics improve feed or water consumption or both. General health of the bird and feed conversion improves. It is reported that ceca of antibiotic fed chicken are larger and filled with greater quantity of moist excreta, compared to the ceca of chickens fed the same diet without an antibiotic.
Reference in this connection may be made to "Nutrition of Chicken", Ed. M.L. Scott, M.C. Nesheim and R.J. Young, Ithaka, New York, 1982, 388-390; "Feeds & Principles of Animal Nutrition", Ed. G.C. Banerjee, Oxford & IBH Publishing Co. Pvt. Ltd., Calcutta, 1988, 375.
The demerits of using antibiotics are highlighted below:
1.Antibiotics are generally non-specific and may also destroy the beneficial organisms in the Gastro Intestinal Tract (GIT).
2.Having destroyed or impaired the beneficial organisms, absorption of nutrients ih the GIT is adversely affected even though the nutrients are present in adequate amounts in the diet, their absorption is hindered and thus is lost to the birds.
3. It is feared that widespread use of antibiotics in food animals can lead to development of resistance in humans.
A classic example is that of Avoparcin. Avoparcin was a well-known glycopetode antibiotic. which was used in many countries as a growth enhancer in various species of livestock including pigs and poultry. In 1995, this product was banned in Denmark and in Germany in 1996. It was banned for use in European Union in 1997. This was because of concerns that the use of Avoparcin was leading to the development of resistance against an important human medicine, Vancomycin and that the resistance could transfer from bacteria in the food chain to man. This could be important as Vancomycin is a so called 'antibiotic of last resort' in human medicine.
Reference in this context may be made to International hatchery practice, 1998Nol.12, No.8. Published by. P.A.P. U.K
4. Some antibiotics are suspected to be carcinogenic. Like for instance, Nitrofurans have been removed from the Canadian market as of February 1st 1993. Concerns about the carcinogenicity of Nitrofurazone in rats and mice based on US data promoted Canadian action. The Branch subsequently ruled that the sale of the feed supplement (drugs) for use in food-producing animals should cease.
Reference in this connection may be made to Animal Pharm, No. 270, February 12th 1993, 13
5. Another major drawback with the use of certain antibiotics is that they are also absorbed in GIT of the bird, along with other nutrients. In such cases a specific withdrawal period is required, during which these absorbed antibiotics are dislodged or metabolized and are not retained in the body in their original form. In case this withdrawal time is not adhered to strictly before slaughter (as is often the case) the bird meat retains the antibiotic(s) and can lead to problems if the bird meat is used for human consumption. Table-2 lists the withdrawal time and limitations for use for certain antibiotics.
TABLE-2
DRUG PRES AUGHTER LIMITATIONS FOR USE TOLERANCE LEVEL
WITHDRAWAL
TIME (PPM)
Aklomide,roxarsone 5 Do not use in egg-laying birds; Aklomide: liver, use as only source of organic (Aklomix-3) muscle,4.5;skin,fat,3.Arseni arsenic c:muscle,eggs,0.5; other by- roducts,2
Aklomide,sulfanitran, 5 Do not use in egg-laying birds; Aklomide and arsenic same roxarsone(No vastat- 3 ) use as only source of organic as above; sulfanitran,0 arsenic
Amprolium 0 For control only several Ei-meria Liver,kidney, 1 ; sp. muscle,0.5;whole eggs,4;egg yoiks,8 Arsenic, same as above
Arsanilic acid or 5 Use as only source of organic Arsenic, same as above sodium arsanilate arsenic
Bacitracin 0 Meat, eggs,0.05(0.02 unit/g)
Buquinolate 5 Use as only source of organic Liver, arsenic kidney,skin,0.4;muscle,0.1 ; eggs,0.2(calculated as arsenic)
Butynorate,sulfanitan, 5 Do not use in egg-laying birds; Butynorate and dinsed,none dinsed,roxarsone(Poly use as only source of organic published;aresenic,same as stat) _ _ arsenic above
Carbomycin 2 Do not use in egg-laying birds; 0
Chlortetracycline 1 Do not use in egg-laying birds Kidney,4; when fed at 500g/900 kg feed muscle,liver,fat.skin, 1 ;eggs. 0
Clopidol(Coyden) Do not use in chickens over 16 Liver and weeks old when feeding 0.025%, kidney, 15;muscle,5 or reduce dosage to 0.0125% 5 days before slaughter
Decoquinate 5 Do not use in egg-laying birds Muscle, 1 ; other tissues,2
Erythromycin(Gallim 1-2 Do not use in egg-laying birds at Eggs,0.025,edible ycin) a level over 185g 900 kg feed tissues.0.125
Estradiol 42 Injected subcutaneously at base ofO monopalmitate skull at not less than 5 weeks of
.age. _ '
Furazolidone (Furox 5 Do not use in egg-laying birds or None published NF-180) in replacements over 14 weeks old
Gentamicin sulfate 35 For use in day-old chickens only None published injection
Hygromycin B 0 8-12 g/900 kg feed 0
Lasalocid sodium 8-12 g/900 kg feed Edible tissues,0.05
Lincomycin 8-12 g/900 kg feed Edible tissues,0.1
Metoserpate Do not use in egg-laying birds 0.02 hydrochloride
(Pacitron)
Monensin 3-5 Do not use in egg-laying birds 0.05 sodium(Coban)
Nequinate(Statyl) Use as only source of organic Edible tissues,0.1 arsenic; do not use in chickens over 16 weeks old
Nicarbazin (Nicarb) 4 ?_ not use in egg-laying birds 4
Nitarsone(Histostat- 5 Use as only source of organic None published 501 ___ arsenic
Nitrofurazone(NFZ,A 5 Do not use for replacement birds None published mifur) over 14 weeks old
3-nitro-4- 5 Use as only source of organic Muscle,eggs,0.5;other byhydroxyphenylarsonic arsenic products^ acid(roxarsone)
Nitromide,sulfanitran 5 Do not use in egg-laying birds Nitromide,none
(Unistat-2) published;sulfanitran,0
Nitromide.sulfanitran 5 Do not use ih egg-laying birds, Nitromide,0.03;sulfanitran.0 (Unistat-3) use as only source of organic ;arsenic, same as above arsenic^ ___
Novobiocin(Albamix) 4 Do not use in egg-laying birds 0 Nystatin _ 0 50-100g/900 kg feecf 0
Oleandomycin Do not use in egg-laying birds Edible tissues,0.15 Ormetoprim 5 Do not use in birds over 16 week Edible tissues,0.1 old
Oxytetracycline 0 50-200 g/900 kg feed Kidney,3; muscle,liver,fat,skin, 1
Penicillin JΛ- 25 g 900 kg feed Edible tissues, egges,0
Penicillin Do not use in egg-laying birds 0 powder(buffered) Robenidine~ Do not use in egg-laying birds Skin and fat,0.2;other edible hydrochloride tissues,0.1 (Robenz)
Spectinomycin Do not use in egg-laying birds Edible tissues,0.1
Streptomycin Administer not more than 4 days. Edible tissues, eggs,0 hydrochloride or do not use in egg-laying birds streptomycin sulfate
Sulfachloropyrazine,s 4 Do not use in birds producing 0 odium monαhydrate eggs for human food
Sιdfadimethoxine,orm5 Do not use in birds over 16 weeks 0.1 for both drugs etoprim(Rotenaid) old
Sulfanitran Do not use in egg-laying birds 0
Sulfaquinoxaline (SQ 10 Do not use in birds producing None published 40,Sulquin-40) eggs for human food
Sulfomyxin Do not administer to egg-laying 0 birds
Tetracycline_ 0.25
Tylosin phosphate 5* Feed at 0-5 days of age; 2nd Edible tissues, eggs,0.2 administration is fed24-48 hrs at3-5 weeks of age
Reference in this connection may be made to John's Veterinary Pharmacology & Therapeutics, Ed. Nicholas, H. Booth, Leslie E.Macdonald, Kalyani publishing, Ludhiana, 5th edition, 1984, 1083-84.
The European Union international conference on antimicrobial resistance that was held in ' Copenhagen (Refer to International Pig Topics, Vol. 3, No.7, 1998, 3) came to several interesting conclusions. The Copenhagen document concluded that most of the delegates felt that the use of antimicrobials for growth promotion could not be justified and growth promoting antimicrobials should be replaced by safer non-antimicrobial alternatives including better farming practice.
Hence it is clear that a safer and effective alternative growth promoter is needed for domestic animals especially for poultry, cattle, birds etc.
As per J. Walter (1980), the characteristic of an ideal growth promoter for domestic animals should have the following essential features:
• Improves performance effectively and economically.
• Not cause cross-resistance to other antibiotics at actual use levels. »Not be involved with transferable drug resistance
•Not cause deleterious disturbances to the normal gut flora
•Not be absorbed from the gut into edible tissues.
•Not be mutagenic or carcinogenic
•Not give rise to environmental pollution • it must be readily biodegradable.
•Be non-toxic to the animal and its human handlers.
In this context, reference may also be made to International hatchery practice. Published by P.A.P. UK, 1998, Vol.l2, No.8, p.3
DEVELOPMENT OF THE INVENTION: After studying the requirements in connection with the development especially of poultry industry, it was learnt that efficacy of the various types of weight promoters hitherto available differ. Further their cost also varies, sometimes proving unaffordable for poultry farmer.
The present invention has been developed to meet the above said requirements
Therefore the main objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals Another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which is very potent, non toxic and safe.
Yet another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which mixes well with feed and ensures homogeneous mixing Still another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which does not require any withdrawal period before slaughter and there are no toxic residues retained in the bird meat.
Yet another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which does not cause deleterious disturbances to the normal gut flora. Further another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which is not absorbed from the gut into edible tissues.
Still another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which is not mutagenic or carcinogenic
Yet another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which does not give rise to environmental pollution and is readily biodegradable.
Another objective of the present invention is to provide an improved herbal composition useful for hepatoprotection and promoting weight gain in domestic animals which is non-toxic to the animal and its human handlers.
In Ayurveda (Indian system of medicine) recommends several medicinal plants useful as herbal feed supplements which are also effective in curing ailments of the liver. Ayurvedic literature like "Vaidya Chintamani, Bhava Prakash Niganthu, Yoga Ratnakara and Charaka Samhita" have references to the herbs capable of being used in the treatment of liver disorders.
The present invention has been developed based on our finding that a synergistic hepatoprotective and weight gain promoting composition can be formulated to meet the above mentioned objectives employing plants judiciously selected from the families of Acanthaceae, Euphorbiaceae, Solanaceae and Nyctaginaceae. From the above said families of the plants used in Ayurveda for hepatoprotective and weight gain promoting in domestic animals we have selected according to the present invention the following plants.
(l)ANDROGRAPHIS PANICULATA
(2)SOLANUM NIGRUM (3)PHYLLANTHUS AMARUS
(4) BOERHAA VIA DIFFUSA
The details of the information about the above said plants which are available in public domain are given below.
1) ANDROGRAPHIS PANICULA TA Part used: Whole plant
Botanical description: Erect or procumbent, herbs or under-shrubs, the branches are often tetragonous. Leaves entire. Flowers in axillary and terminal, often panicled, racemes, unilateral bracts small, bracteoles minute or absent. Calyx 5-partite, Corolla small, tubular at base. prominently 2-lipped, the upper slightly bifid, the lower usually deflexed, 3-Iobed and coloured. Stamens 2 filaments broad, anthers 2-celled. Ovary 2-celled, ovules 2-6 in each cell, style slender. stigma minutely bifid. Fruit an oblong or. elliptic capsule compressed at right angles to the septum,
4-12 seeded, the retinacula acute or rounded. Seeds hard, deeply rugosely pitted glabrous. (Ref.
Matthew K.M., "The Flora of Tamil Nadu Carnatic", Pub. The Rapinat Herbarium, Tiruchirapalli.
India. 1983, Vol. 2, 1152) Medicinal" uses: The plant is bitter, acrid, cooling, vulnerary, antipyretic, antiperiodic, anti- mflammatory, expectorant, depurative, sudoforic, anthelmintic, digestive and stomachic. It is useful in rryperdypsia, burning sensation, wounds, ulcers, chronic fever, malarial and intermittent fevers. irLflairirnations, cough, bronchitis, skin diseases, leprosy, pruritis, intestinal worms, flatulence colic. diarrhoea, dysentery, hemorrhoids (Wealth of Asia ,NISCOM, CSIR, New Delhi, 1996 -.Indian Medicinal Plants, A compendium of 500 species. Orient Longman, 1993; Vol. 1: 135; Nadakarni K.
M. Hie Indian Materia Medica, Pub. Bombay Popular Prakashan 1 93; Vol. 1 : 101)
Phytochemistry: The main constituents of Andrographis paniculata are diterepene lactones, viz.. andrographolide, neoandrographolide, andrographiside and flavones viz., oroxylin, wogonin, andrographidines A, B, C, D, E, F (Indian Herbal Pharmacopoeia, Vol. I, p.18-29. Joint Publication of IDMA (Mumbai) and RRL (Jammu-Tawi; Matsuda T, et al "Cell differentiation -
Inducing Diterpenes from Andrographis pa iculata Nees", Chem. Pharm. Bull, 1994, 42(6),
1216- 1225)
Pharmacology: Hepatoprotective effect of andrographolide (the major active diterpenoid lactone of the plant Andrographis paniculata) was studied in many experimental models. In a study a dose of 300 mg/kg of the extract was selected to study hepatoprotective action against CC14-induced liver damage, was found to be effective in preventing liver damage, which was evident by morphological, biochemical and functional parameters (Rana, A.C; Avadhoot, Y;
"Hepatoprotective effects of Andrographis paniculata against carbon tetrachloride-induced liver damage", Archives of Pharmacological Research, 1991; 14(1), 93-95). Andrographolide was found to be more potent than silymarin, a known hepatoprotective drug (Visen, P.K.S; Shukla, B; Patnaik,
C.K; Dhawan, B.N; "Evaluation of hepatoprotective activity of andrographolide isolated from the plant Andrographis paniculata". Proceedings 24 , Indian Pharmacological Society, Conference,
1991; 12)
2) SOLANUM NIGRUM Part used: Whole plant
Botanical description: An erect annual herb,, -stem glabrous or pubscent, much divaricately branched. Leaves numerous, ovate, lanceolate, subacute or accuminate, glabarous, thin entire.
Flowers 3-8 in extra-axillary drooping sunbumbellate cymes; fruits purlish black or reddish berries.
Seeds many, discoid, minutely pitted yellow (Indian Medicinal Plants, A compendium of 500 species, Orient Longman, 1993,5,160-163)
Medicinal uses: The plant used as an antispasmodic and in the treatment of cirrhosis of the liver.
Berries are considered to posses tonic, diuretic and cathartic properties and are useful in heart diseases (Wealth of Asia ,NISCOM, CSIR. New Delhi, 1996 Vol. 1: 135)
Phytochemistry: The plant contains protein, fat, minerals, carbohydrates, riboflavin, nicotinic acid. vitamin-c, carotene, glucose, fructose, steroidal alkaloids viz. solamargine, solasonine, solanigrine. etc. (Wealth of Asia ,NISCOM. CSIR, New Delhi.1996)
Pharmacology: In a study conducted on rats there was increased feed consumption and increase in body weight in female rats which received Solanum nigrum cooked leaves in feed when compared to control group. Further, Solanum nigrum improved the quality and quantity of nutrients like Vit. C, β carotene, protein and aminoacids in feed which probably favour on increase in the activity of liver drug metabolizing enzymes. In another study there was increase in body weight, liver weight and liver protein in female weaning rats which received Solanum nigrum extract when compared to control group (Saxena A and NK Garg Ind J.exp. Bio., 1979 17(7),662-664).
The hepatoprotective activity of Solanum nigrum crude plant extracts may be due to their ability to suppress the oxidative degradation of DNA in the tissue debris. (Sultana S., et a! "Crude extracts of
hepatoprotective plants, Solanum nigrum and Cichorium intybus inhibit free radical-mediated DNA damage." J. ofEthnopharmacology, 1995, 45, 189-192). 3) BOERHAA VIA DIFFUSA Part used: Whole plant Botanical description: A perennial diffuse herb with stout root stock and many procurement branches; leaves simple, opposite, short petioled in unequal pairs, ovate-oblong, acute or obtuse, subcordate at base, glabrous above and whitish beneath ; flowers pale rose colored, small, short stalked, in irregular clusters of terminal panicles at the ends of branches; fruits highly viscid, easily detachable, one-seeded, indehiscent with a thin peήcsrp(Indian Medicinal Plants, A compendium of 500 species, Orient Longman, 1993 ; Vol. 1 : 253-255)
Medicinal uses: The plant is bitter, astringent, cooling, anthelmintic, diuretic, emetic, expectorant. It is used in the treatment of jaundice (Wealth of Asia ,NISCOM, CSIR, New Delhi, 1996 lndian Medicinal Plants , A compendium of 500 species. Orient Longman, 1993; Vol. 1: 253-255) Pbytochemistry: The major constituent namely Punarnavoside is found in 0.03-0.05%.Other minor consdtuents include rotenoids viz., boeravinones A,B,C,D, & E ; lignans liridodendrin etc. Pharmacology: The aqueous extract of Boerhaavia diffusa roots (2 ml/kg rat administration) has more hepatoprotective activity than powder forrri. probably due to the better absorption of the liquid form through the intestinal tract (Rawat AKS et al "Hepatoprotective activity of Boerhaavia diffusa L. roots a popular Indian ethnomedicine" J. ofEthnopharmacology, 1997,56,61 -66). 4) PHYLL4NTHUS AMARUS Part used: Whole plant
Botanical description: A small erect herb, stem terete, younger parts rough; leaf elliptic oblong to obvate; Flowers axillary, proximal 2-3 axils with unisexual 1-3 male flowers and all succeeding axils with bisexual cymules. Male flowers-pedicel long, calyx 5, sub equal, oblong, elliptic, apex acute, hyaline with unbranched mid rib; disc segments 5, rounded, stamens 3. filaments connate. Female flowers-pedicel long, calyx lobes 5, ovate-oblong, acute at apex; disc flat deeply 5 lobed, lobes often toothed at apex, styles 3, free, shallowly bifid at apex. Capsule oblate and rounded, seeds triangular with longirudinal ribs (Bagchi G.D, Srivastava G.N , Singh S.C, Distinguishing features of medicinal herbaceous species of Phyllanthus occuring in Lucknow District (U.P) India. Int. J. Plwrmacognosy, 1992. 30(3), 161-168)
Medicinal uses: The plant is bitter, astringent, cooling, diuretic, stomachic, febrifuge and antiseptic. It is useful in dropsy, jaundice, diarrhoea, dysentery, intermittent fevers, diseases of urino-genital system, scabies ulcers and wounds (Wealth of Asia, NISCOM, CSIR, New Delhi. 1996: Indian Medicinal Plants. A compendium of 500 species, Orient Longman. 1995; Vol. 4: 252- 255; Bhava prakash nigunia. Motilal banarsidas publications, 1998, 273)
Phytochemistry: The major lignans Phyllanthin and Hypophyllanthin has been reported to exhibit antihepatotoxic activity. Lignans - a diarylbutane, Phyllanthin and an aryltetrahydronaphthalene, hypophyllanthin (Indian Herbal Pharmacopoeia, pub: Regional Research Laboratory, Jammu Tawi & Indian Drug Manufacturer's Association Mumbai, 1999, 2, 85 - 92) Pharmacology: Phyllanthus amarus at the dose of 0.66 g/kg in each rat orally was found to be effective, not only against liver damage from CC14 in rats but also effective in the liver regeneration (Sane R.T, Kuber V.V, Chalissery M.S., Menon S, Hepatoprotection by Phyllanthus amarus and Phyllanthus debili in Ccl4 induced liver dysfunction, Current Science, 1995, 68 (12), 1243 - 1246); In another study Phyllanthus amarus was tested on hepatitis B virus. The alcoholic extracts were effective against HBV antigens, the butanol extract being the most potent. The active fractions inhibited the interaction between HBsAg/HbeAg and corresponding antibodies suggesting anti- HBs, anti-Hbe-like activity and also an effect on HBV-DNA. ("In- vitro effect of Phyllanthus amarus on hepatitis B virus", Mehrotra R et al., Indian J. Med. Res. 1991, 93(A), 71-73]. The crude powders of the above mentioned plants were administered individually to domestic animals ( Poultry birds) to determine the hepatoprotective and weight gain promoting activities in the following manner
Day old chicks were obtained from M/s. Venkateshwara Hatcheries (Vencobb hybrid line) with equal sex ratio for the study and divided into control and treated groups. Control group received the feed (Lipton's Gold Mohur feed from Hindustan Lever Limited) and treated groups received the same feed mixed with the required doses of the test material( namely the above said plants ). The birds were fed for a period of 42 days. Feed consumption ratio, body weight, livability were recorded as the parameters. Additional parameters like Bursa weight, serum glutamate pyruvate transami ase (SGPT) and dressing percentage were also recorded. The results are shown in Table 3 ~ TABLE-3
Group Test Strain of Feed used Avg. b.wt. (g) + Improvement Avg. FCR + Livability material bird SEM (%) SEM (%)
250 g/ton of feed
I Control 1665 + 1S5 0 2.128 + 0.029 92.46 π Plant 1 * 1764 + 160 5.9 2.113 ± 0.021 94.83 m Plant 2*
-hvbrid line Mohur 1800 ± 158 8.1 2.119 ± 0.031 91.64 rV Plant 3* feed 1810 + 149 8.7 2.012 + 0.026 95.32 V"" Plant *- 1797 + 163 7.9 2.216 + 0.031 94.21 n = 50.
In the above table Plant 1 relates to Andrographis paniculata;, Plant 2 relates to Solanum nigrum; Plant 3 relates to Phyllanthus amarus and Plant 4 relates to - Boerhaavia diffusa
From the information given in the Table 3 we have observed that above plants have not only hepatoprotective activity but also weight gain promoting properties in domestic animals such as poultry birds. Based on our above said observations we have developed the composition which is effective as hepatoprotective and weight gain promoter in domestic animals such as poultry birds.
Accordingly, the present invention provides, a herbal composition useful for hepatoprotection and promoting weight gain in domestic animals comprising
(i) 25- 35% w/w of the total weight of the composition of the powder of t e plant of Andrographis paniculata
(ii) 20-30% w/w of the total weight of the composition of the powder of the plant of Phyllanthus amarus (Hi) 20-30% w/w of the total weight of the composition of the powder of the plant of Solanum nigrum and
(iv) 15- 25% w/w of the total weight of the composition of the powder of the plant of Boerhaavia diffusa
In a preferred embodiment of the present invention any part of the above said plants may be used individually or all the parts together as per the requirements .
According to another feature of the invention the composition may be formed into any oral dosage forms like, tablets, bolus, capsules, syrups and liquids etc. For facilitating making the composition in the above said dosage forms, pharmaceutical excipients, which are usually employed to prepare such oral dosage form may be employed . By way of examples recipients like starch, pre- gelatinized starch, dicalcium phosphate or a mixture thereof may be used.
According" to another feature of the present invention a herbal composition may also contain preservatives which may be selected from propyl paraben sodium, methyl paraben sodium or bronopol or a mixture thereof and the like .
According to yet another feature of the present invention there is provided a process for preparing the herbal composition useful for hepatoprotective and weight gain promotion in domestic animals which comprises
(i) mixing a first mixture of 25-35% w/w of the powder of the plant Andrographis paniculata and
20-30% w/w of the powder of the plant Phyllanthus amarus then, mixing the resultant first mixture with (ii) a second mixture of 20-30% w/w of the powder of the plant of Solanum nigrum and 15-25% w/w of the powder of the plant of Boerhaavia diffusa
(iii) the powders having a mesh size of 5 to20 and
(iv)the resulting composition is finally pulverized by conventional methods to a mesh size of 70-
100 and the composition having a mesh size of 70- 100 In a preferred embodiment of the invention for making the powders any part of the above said plants individually or all the parts together may be used as per the requirements
Before making the powders , the parts of the plants or the whole plants are cleaned to avoid foreign materials , cut and chopped to make it easy to make the powders ..
According to another feature of the invention the composition may be formed into any oral dosage forms like, tablets, bolus, capsules, syrups and liquids etc by conventional means . For facilitating making the composition in the above said dosage forms, pharmaceutical excipients, which are usually employed to prepare such oral dosage form may be employed . By way of examples recipients like starch, pre-gelatinized starch, dicalcium phosphate or a mixture thereof may be used.
According to another feature of the present invention a herbal composition may also contain preservatives which may be selected from propyl paraben sodium, methyl paraben sodium or bronopol or a mixture thereof and the like .
The invention is described in detail in the Examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.
Example 1
An amount of 150gms (30%w/w) of Andrographis paniculata (whole plant) and lOOg s (20%/w) of Phyllanthus amarus (whole plant) were cleaned and chopped in a chopping machine to obtain a mesh size of 8 to 10 mesh and mixed together . Similarly 150 gms (30%w/w) of Solanum nigrum whole plant after cleaning and chopping was powdered in a hammer mill to a sieve size of 8 to 10 mesh was mixed with lOOgms (20% w/w) of the powder having the mesh size of 8 to 10 of the plant Boerhaavia diffusa, (whole plant). The above said two mixtures were mixed together and the resulting composition was pulverised in a pulveriser to a sieve size of 70 to 100 The above composition for convenience is henceforth referred to as Composition A
Each of the two above said compositions were subjected to the following trials.
Example 2 An amount of 125gms (25%w/w) of Andrographis paniculata (whole plant) and 150gms (30%/w) of Phyllanthus amarus (whole plant) were cleaned and chopped in a chopping machine to obtain a mesh size of 8 to 10 mesh and mixed together . Similarly 100 gms (20%w/w) of Solanum nigrum
whole plant after cleaning and chopping was powdered in a hammer mill to a sieve size of 8 to 10 mesh was mixed with 125gms (25%w/w) of the powder having the mesh size of 8 to 10 of the plant Boerhaavia diffusa, (whole plant). The above said two mixtures were mixed together and the resulting composition was pulverised in a pulveriser to a sieve size of 70 to 100 5 The above composition for convenience is henceforth referred to as Composition B
Each of the two above said compositions were subjected to the following trials.
Experimentally aflatoxicosis was induced with aflatoxicin Bi, on broilers and efficacy of two Compostions (Example 1 and Example 2) as hepatoprotective and weight gain promoter was o assessed in 300 birds. The various parameters studies employed were weekly gain in body weights, feed consumption and FCR. Biochemical assessment was made using SGOT, SGPT, Albumin, Globulin and Albumin globulin ratio, Haematological parameters were also included like haemoglobin, packed cell volume. The humoral acquired immunity and cell mediated immunity were also included to evaluated the immune status. Gross and histopathological lesions of the 5 organs collected namely liver, kidney, bursa of Fabricius, etc. were also recorded. Composition B (Example 2) treated group showed significant improvement over the aflatoxin fed birds in terms of body weight gain, feed consumption, FCR, etc. The im une status of the birds revealed improved cell mediated and humoral immune response. These results can be seen in the Table 4 0 Table 4 Showing the efficacy of the Compositions A & B (Example 1 and Example 2 ) in aflatoxin induced hepatotoxicity
Test 1 shows- Example 1 (Composition A) Test 2 shows- Example 2 (Composition B)
The above study clearly indicates that both the Compositions are effective in protecting chicks against aflatoxin induced hepatotoxicity. However since Composition B (Example 2) was more potent it was selected for further studies.
Composition B (Example 2)was tested for its efficacy at different dosages for its hepatoprotective and weight gain promoter activity in two different dosages to chicks (Vencobb hybrid line) Control group received the feed (Lipton's Gold Mohur feed from Hindustan Lever Limited) and treated groups received the same feed mixed with the required doses of the test material. The birds were fed for a period of 42 days. Feed consumption ratio, body weight, livability were recorded as the parameter. Additional parameters like Bursa weight, serum glutamate pyruvate transaminase (SGPT) and dressing percentage were also recorded. Composition B (Example 2) at 250g/ton dosage afforded maximum hepatoprotection and weight gain which was comparable with a dosage of 500g/tonne of feed. The results are given in Table 5
Table 5
Test 2 shows the Example 2 ( Composition B ) - 250 g/ton ;
Test 2- shows the Example 2 ( Composition B ) 500g/ton
Form the information provided in Table 3 ( for individual plants - column 6 ) and Table 5 ( for the mixture of the plants - Column 6) it would be observed that the improvement percentage has increased 3 to 4 times when the mixture of the plants as per the present invention is administered . This improvement is due to the synergistic combination of the plants used in the specified quantities and method of preparing the composition .
Accordingly the composition of the present invention is not a mere admixture of the ingredients employed but is a result of a unexpected synergistic combination of the ingredients employed Study of acute toxicity of the Example 2(Composition B)
Sixteen Albino Swiss mice were taken, divided into two groups and fasted for 16 hours. One group served as the control and received the 'vehicle'. The second group received the feed supplement (Composition B ) powder as a 0.5% suspension in crystalline microcellulose at a dose of 3000mg/kg mice body weight.
There were no symptoms of toxicity (gross observation) and death still 72 hours. 56mg/kg mice body weight was found to be the effective antihepatotoxic dose and the therapeutic index was found to be >53 times. Hence it can be inferred that the feed supplement (Composition B) is very safe.
Comparative evaluation of the powder and liquid forms of the Composition B :
The composition B was tested for its efficacy as hepatoprotective in its crude drug form and as a liquid The liquid form of the Composition B was prepared by mixing the powder with water
Male albino rats of either sex weighing 200-250gms were taken and the composition B, both the powderf 250gm / ton of feed )and the liquid forms( (@ 2.5 mg / kg of body weight) separately were administered for two weeks, mixed with feed or in drinking water. Carbon terra chloride was administered after 48 hours to induce hepatotoxicity or liver damage. The data was analysed using ANOYA and Student's t-test. And the result is given below
Group Control CTC Composition B Composition B (as powder) (as liquid)
SGPT(U L) 55+8 1278+140* 160+78+ 348+83"
* pO.OQOl compared to other groups -p<0.005
Field trials of Composition B in powder form were conducted at various agroclimatic condition, feeds and strains of birds in India on layers and broilers have shown an improvement in body weight, livability and production number. Composition B has also shown to reduce the egg shell breakage and reduce mortality in layers as can be seen from the Table 6 .
Table 6 RESULTS OF CONTROLLED/FIELD TRIALS IN BROILERS
* The flock was sold little earlier because of better market prices.
Z -Composition B C-CONTROL group * % improvement over control group
Conclusion: The results indicate that the performance enhancing activity of the composition B is very consistent and it is independent irrespective of strain of broiler, feed (branded/unbranded) and agro climatic conditions. The composition of the present invention also improves feed metabolism and digestion and thus helps in better growth, weight gain and general health. It acts in the following ways:
1. Increases secretion and flow of bile from the liver and thereby assists fat digestion and assimilation.
2. Shows potent hepatoprotective and anti-hepatotoxic activity, guards the liver parenchyma against toxic effects of toxins, antibiotics, -mthelrnintics etc.
3. Exhibits strong hepatogenic activity and helps in the regeneration of damaged liver tissue.
4.1n cases of liver damage indicating delayed BSP clearance, rise in bilirubin, low A/G ratio and prolonged prothrombin time (clotting time), therapy enables all the above parameters, to return to normal range.
5. Stimulates glycogenesis and glyconeogenesis in the liver. Also helps in restoring cholesterol metabolism in the liver.
ό.Research has indicated that its supplementation in feed is effective not only in inhibiting damages caused by Aflatoxins in livestock but also in reversing the damaging effects of Aflatoxin with improved growth, weight gain, early maturity and better farm productivity.
Indications: Jaundice,Hepatitis.Ailatoxicosis,To improve the body resistance,Debility and general weakness,Toxaemia,During Convalescence,Fatty liver diseases,Leg weakness,For improving feed efficiency, general health and productiorLFor better livability,As a adjunct or after antibiotic/anthelmintic/chemical drugs therapy to restore normal detoxification and liver functions.
Advantages of the invention
Special benefits of the invention:
Broilers Layers
1. 6-10% higher weight gain Attainment of uniform sexual maturity
2. 4-9% improvement in FCR Better hen housed production
3. Nullifies the ill-effects of feed related toxins, i.e.Better FCR Aflatoxins, chemicals and pesticides
4. Enhancement of general health and henceReduction in thin shell and egg breakages improvement in livability in the older birds
5. Shortens the growing period Nullifies the ill-effects of feed related toxins, i.e. Aflatoxins, chemicals and pesticides
Additionally, the present invention has other advantages such as
1.It is safe and non-toxic
2. Mixes well with feed-ensures homogeneous mixing
3. Highly cost effective 4.There is no withdrawal period required before slaughter and there are no toxic residues retained in the bird meat.
5. It is very potent, non toxic and safe
6. It does not cause deleterious disturbances to the normal gut flora which is not absorbed from the gut into edible tissues. 7. It is not to be mutagenic or carcinogenic
8. It does not give rise to environmental pollution and is readily biodegradable.
9. It is non-toxic to the animal and its human handlers.
Claims
1. A herbal composition useful for hepatoprotective and promoting weight gain in domestic animals comprising (i) 25- 35% w/w of the total weight of the composition of the powder of the plant of Andrographis paniculata
(ii) 20-30%) w/w of the total weight of the composition of the powder of the plant of Phyllanthus amarus
(in) 20-30% w/w of the total weight of the composition of the powder of the plant of Solanum nigrum and
(iv) 15- 25% w/w of the total weight of the composition of the powder of the plant of Boerhaavia diffusa and the composition having a mesh size of 70- 100
2. A herbal composition as claimed in claim 1 wherein any part of the above said plants is used individually or all the all the parts together as per the requirements
3.A herbal composition as claimed in claims 1 & 2 wherein the composition is formed into any oral dosage forms like, tablets, bolus, capsules, syrups and liquids etc.
4 A herbal composition as claimed in claims 1 to 3, wherein the composition contains pharmaceutical excipients, which are usually employed to prepare such as starch, pre-gelatinized starch, dicalcium phosphate or a mixture thereof .
5. A herbal composition as claimed in claim 3 & 4 wherein the composition also contains preservatives selected from propyl paraben sodium, methyl paraben sodium or bronopol or a mixture thereof and the like.
6. A process for the preparation of a herbal composition as claimed in claims 1 to 5 which comprises
(i) mixing a first mixture of 25-35% w/w of the powder of the plant Andrographis paniculata and 20-30% w/w of the powder of the plant Phyllanthus amarus then, mixing the resultant first mixture with
(ii) a second mixture of 20-30% w/w of the powder of the plant of Solanum nigrum and 15-25% w/w of the powder of the plant of Boerhaavia diffusa (iii) the powders having a mesh size of 5 to20 and
(iv)tbe resulting composition is finally pulverized by conventional methods to a mesh size of 70- 100
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2001/000178 WO2003030635A1 (en) | 2001-10-11 | 2001-10-11 | A herbal hepatoprotective and weight gain promoter and a process thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2001/000178 WO2003030635A1 (en) | 2001-10-11 | 2001-10-11 | A herbal hepatoprotective and weight gain promoter and a process thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003030635A1 true WO2003030635A1 (en) | 2003-04-17 |
Family
ID=11076390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2001/000178 WO2003030635A1 (en) | 2001-10-11 | 2001-10-11 | A herbal hepatoprotective and weight gain promoter and a process thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003030635A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011074001A2 (en) | 2009-12-18 | 2011-06-23 | Shiv Prakash Ratnam | A hepatoprotective herbal composition |
CN105519493A (en) * | 2016-01-28 | 2016-04-27 | 云龙庆明孵化科技有限公司 | Breeding method of geese |
CN105918240A (en) * | 2016-04-25 | 2016-09-07 | 青岛奕奕和农牧科技有限公司 | Cultivation method for pheasant by using Chinese herbal medicine |
RU2649808C1 (en) * | 2017-08-01 | 2018-04-04 | Федеральное Государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт мясного скотоводства | Method for reducing loss of productivity of meat bulls in industrial complex under technological stresses |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837257A (en) * | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
US6136316A (en) * | 1996-04-17 | 2000-10-24 | Dabur Research Foundation | Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection |
-
2001
- 2001-10-11 WO PCT/IN2001/000178 patent/WO2003030635A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136316A (en) * | 1996-04-17 | 2000-10-24 | Dabur Research Foundation | Hepatoprotective compositions and composition for treatment of conditions related to hepatitis B and E infection |
US5837257A (en) * | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011074001A2 (en) | 2009-12-18 | 2011-06-23 | Shiv Prakash Ratnam | A hepatoprotective herbal composition |
CN105519493A (en) * | 2016-01-28 | 2016-04-27 | 云龙庆明孵化科技有限公司 | Breeding method of geese |
CN105918240A (en) * | 2016-04-25 | 2016-09-07 | 青岛奕奕和农牧科技有限公司 | Cultivation method for pheasant by using Chinese herbal medicine |
RU2649808C1 (en) * | 2017-08-01 | 2018-04-04 | Федеральное Государственное бюджетное научное учреждение Всероссийский научно-исследовательский институт мясного скотоводства | Method for reducing loss of productivity of meat bulls in industrial complex under technological stresses |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Uko et al. | Some biological activities of Garcinia kola in growing rats. | |
JP2000139405A (en) | Food additive and health food | |
KR101716763B1 (en) | Breeding Method for Crickets Comprising Ginsenoside Type Saponin and Polysaccharide from Panax ginseng and their Extracts and Food Composition | |
CN105166544A (en) | Pig mixed feed and preparation method thereof | |
CN1036115C (en) | Fodder additive for reducing egg and chicken cholesterol content | |
CN104222680B (en) | Loach specific complex immunostimulant and its preparation method | |
KR20040013137A (en) | Remedies | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
KR100725926B1 (en) | Chicken feed composition containing garlic | |
KR101807800B1 (en) | Additives for stock feed comprising | |
KR101687558B1 (en) | A composition containing natural materials extract as an active ingredient for treatment of constipation, and manufacturing method of the same | |
WO2003030635A1 (en) | A herbal hepatoprotective and weight gain promoter and a process thereof | |
CN101244164A (en) | Medicament for preventing and treating hydropsy of pigling | |
JPH08191668A (en) | Pet food | |
Amsathkumar et al. | Nutrient utilization and performance of endotoxin exposed kids supplemented with phytogenic feed additive | |
EP1312370B1 (en) | Composition comprising dried whole egg for treating hepatitis | |
CN105535094A (en) | Traditional Chinese medicine composition for facilitating beast, bird and fish production performance | |
KR100730291B1 (en) | Feed additive composition containing onion and herbal medicine and its manufacturing method | |
CN109043177A (en) | A kind of Chinese medicinal herb pig feed | |
KR20220006183A (en) | Feed additive using herbal medicine and method for manufacturing thereof | |
JP2958198B2 (en) | Analgesic pharmaceutical composition | |
CN107019774B (en) | Traditional Chinese medicine composition for treating intestinal diseases of livestock and poultry and application thereof | |
CN116370574B (en) | Traditional Chinese medicine composition for preventing and treating gosling gout and preparation method thereof | |
CN111387356A (en) | Chinese herbal medicine feed additive for preventing diarrhea of young ruminants and preparation method and application thereof | |
JP2003171289A (en) | Analgesic pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CR CU CZ DE DK DZ EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |